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INTRODUCTION
The thymus remains one of the least explored organs in clinical practice, which can be 
explained, at least in part, because it is of difficult access 
for histopathological studies. On the other hand, there 
is growing evidence that the thymus may be affected 
both in congenital diseases and as a consequence of 
immunosuppressive medications, infections, nutritional 
disorders and several other clinical situations1,2. Until 
very recently, there were not many tests available for the 
functional assessment of the thymus. Its morphology, which 
was visualized through imaging techniques, and the study 
of subpopulations of peripheral T-cells were the only means 
to analyze indirectly the functional state of the organ . The 
advent of the technique for measuring the TRECs (T-cell 
receptor excision circles or thymic recent emigrant cells) 
in the peripheral blood has little more than a decade and is 
still restricted to research laboratories. 
Much of what we know about the thymus comes 
from experimental studies, particularly those with murine 
and bird models. The increase in knowledge about the 
functions and disorders of the thymus in the last decades 
has been remarkable, and contrasts with the scarcity of 
data from human beings that allow practical progress in the 
identification and therapeutic approach of thymus diseases. 
HIV infection and the post-bone marrow transplant in 
neoplastic diseases have been the situations with more 
documented information on thymus function, in addition 
to the most recent interest in the aging process and means 
to promote its reversal or to delay it1,3. The identification 
of the Aire (autoimmune regulator) transcription factor, 
its role in the phenomenon of central tolerance and the 
discovery of a human disease caused by mutations in 
the AIRE gene also represent recent milestones in the 
understanding of the thymus4,5. The thymus was described 
about two thousand years ago by the renowned Roman 
physician Claudius Galen (130-200 AD), who was born in 
Pergamon, and is considered to be the father of Anatomy. 
The name “thymus” was given by Galen himself, because 
the organ (body) reminded him of thyme leaves (Thymus 
in Latin). It is worth clarifying that the plant was burned 
as incense. Throughout history and even until today, the 
organ is still wrapped in an aura of mystery, and there 
are indications that for the Greek the word thymus meant 
“active soul”, the “perishable soul” and that it would be 
equivalent to reason and conscience. Only in 1961, with the 
experimental studies of the Australian physician Jacques 
Miller, consistent scientific data appeared, data that allowed 
for conclusions about its function, and that showed for the 
first time the thymus as a gland with a relevant role for the 
development of the immune system6.
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In this paper, a brief review on the structure of the 
human thymus, its main functions, developmental aspects, 
means for its functional assessment and some thymic 
congenital diseases are presented.
Functions of the Thymus
The thymus is a primary lymphoid organ that 
plays a critical and unique role in the development of 
T-cells, providing the ideal microenvironment so that the 
precursors of lymphocytes derived from the bone marrow 
can proliferate, undergo the rearrangement of their receptor 
and so that their differentiation into mature T-cells can 
occur. When this differentiation occurs, these T-cells are 
able to establish an effective immune response, and then 
leave the thymus, go to the blood and to the peripheral or 
secondary lymphoid organs, that is, the spleen, lymph nodes 
and the mucosal associated lymphoid tissue8,9.
Another crucial (and also unique) function of the 
thymus is related to the induction of tolerance to the body’s 
own antigens, thereby protecting it from autoimmune 
aggression. This function is represented by phenomena 
of: i) negative selection of potentially autoreactive T cells 
(central tolerance); and ii) generation of natural regulatory 




The thymus is essentially a lymphoepithelial 
organ and contains two anatomically and functionally 
distinct compartments, that is, the medulla, in the central 
part, surrounded by the cortex. Both compartments 
are formed by two major cellular components: i) the 
lymphoid component, rich in developing thymocytes 
and ii) the thymic stroma, consisting mainly of epithelial 
cells (Figure 1)8,9,10. Other cells that are also present in 
the thymus are (the) dendritic cells, macrophages and B 
cells, and the role of the latter lineage is still not quite 
elucidated. The reciprocal interactions between epithelial 
cells and thymocytes are necessary for the development 
of both the lymphoid and the epithelial components of 
the thymus, resulting in the aforementioned functions. 
Thus, thymocytes release trophic factors essential to the 
development of the three-dimensional epithelial network, 
while the epithelial cells regulate the development of the 
T cells through the expression and presentation of the self-
antigens by the major histocompatibility complex (MHC)10. 
There are two examples of primary immunodeficiencies 
(PID) in which the thymus is not developed and that 
demonstrate very well the mutual interdependence between 
the lymphoid and epithelial components of the organ11. 
In severe combined immunodeficiencies (SCID), some 
mutations seriously harm the development of precursors 
of T cells, which fail to infiltrate the thymus during its 
development, while in DiGeorge syndrome (22q11.2 
deletion syndrome), a defect in the development of the 
organ per se occurs12. In SCIDs, hematopoietic stem cell 
transplantation is the most effective therapy and induces 
the development of the epithelial component of the thymus 
after lymphoid reconstitution, while in the severe cases 
of DiGeorge syndrome, transplantation of the epithelial 
component of the thymus alone is enough to restore the 
immune system of the affected child13. 
The development of the T cells is started by the 
migration of the so-called early thymic progenitors (ETP) 
from the bone marrow to the thymus8,14. The ETPs enter 
the thymus through the postcapillary venules of the 
corticomedullary junction, and begin to migrate towards 
the subcapsular region of the thymic cortex as double 
negative cells, that is CD4-CD8-. During the migration, 
the progenitor cells undergo differentiation resulting in 
the rearrangement and expression of its receptor (T cell 
receptor - TCR), and in the expression of the CD4 and 
CD8 components (double positive cells – DP, in the cortical 
region) of the receptor. After the expression of the TCR 
and of the co-receptors, the thymocytes are submitted to a 
positive selection process, during which the self-peptides 
presented by the MHC molecules on the cortical epithelial 
cells regulate the differentiation of only a small percentage 
of immature thymocytes so that they become mature T cells. 
The DP thymocytes whose TCR fail to interact or react 
with low affinity to the self-peptides-MHC complexes do 
not receive enough signals to survive and are eliminated 
through the process named death by neglect. “Positively” 
selected thymocytes, that is, those receiving the signal for 
survival in the cortex, migrate to the thymic medulla where 
they will undergo the so-called negative selection, whose 
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main goal is to eliminate thymocytes which are potentially 
reactive against the body’s own tissues, that is, autoreactive 
thymocytes. The thymocytes (here already as CD4 + or 
CD8 + single positives) displaying TCRs that have high 
or inappropriate affinity for the self-peptides (here tissue-
restricted antigens - TRAs), whose expression is regulated 
by the previously mentioned Aire and which are presented 
by the epithelial cells are then eliminated within the thymic 
medulla. Thus, the consecutive positive selection and 
negative selection processes should originate an extensive 
repertoire of immunocompetent T cells which is ideally free 
of autoreactive T cells and respond to non-self antigens. 
After a period of maturation subsequent to the selection, 
single positive T cells (CD4+CD8- and CD4-CD8+, whose 
TCRs will react with cells presenting Class I and Class 
II MHC, respectively) leave the thymic medulla and go 
straight to the periphery. In the thymic medulla there are 
structures that are quite typical of the organ, represented by 
the Hassall’s corpuscles - CH (Figure 1), whose function 
remains to be fully clarified.   The epithelial component 
of the thymus has its origin in the endoderm of the third 
pharyngeal pouch quite early in vertebrate ontogeny, which 
occurs around the sixth week of gestation in humans. The 
expression of the gene that codifies the Foxn1 (forkhead box 
protein N1) transcription factor in cells of the pharyngeal 
epithelium is considered to be the mark of the destination 
for the formation of the thymus9. The Foxn1 is essential for 
thymopoiesis and regulates the expression on the epithelial 
cells of key factors in the attraction of the hematopoietic 
precursors to the embryonic thymus, and infiltration by 
these precursors starts from the 60th day of gestation in 
humans on. The tissue differentiation of the thymus in 
cortex and medulla is completed between the 14th and 16th 
week of gestation, continuing its growth until it reaches 
the greater weight in relation to the body weight little 
before birth8. The organ continues to grow during the first 
months of extrauterine life and commonly reaches large 
volumes when compared to the rib cage in the first two to 
three years of life, representing the “big thymus” which is 
characteristic of infants and well-known by pediatricians 
(Figure 2)15. It continues to grow until adolescence, when 
it reaches its highest weight (about 40g), and from then 
on it begins to involute, with reduced size and weight of 
the cortical and medullary functional compartments (both 
the number of thymocytes and of epithelial cells), which 
are progressively replaced by adipose tissue. It is known 
that even during the process of involution, thymopoiesis 
continues to occur, originating new naïve T cells, even if 
in progressively smaller amounts, in particular after the 7th 
and 8th decade of life3,16.
Figure 1: Histological aspects of the thymus of a 10-month-old infant with surgical congenital heart defect (source: Lima30)
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Figure 2: Image of a bilobed thymus seen on a chest radiograph 
of a 18-month-old eutrophic child, with acute viral respiratory 
infection (courtesy of the Children’s Hospital Radiology Service, 
FMUSP Clinical Hospital)
Assessment of thymic fuction 
In clinical practice, the methods for the assessment 
of thymic function are still incipient, restricted to research 
protocols, and has focused on: i) imaging methods that 
show the variations in the size of the organ. At the moment 
computed tomography is considered the best method, but 
its use in Pediatrics is quite limited because of the large 
amount of X-ray required to generate images Nowadays 
it would definitely not be acceptable from an ethical 
point of view to use computed tomography in protocols 
of research with children, and even in clinical practice, 
this technique should be restricted to situations where 
other potentially less damaging-to-the-tissues radiation 
(ultrasonography, conventional radiography and MRI) 
are not able to generate images with the same informative 
power17; ii) Assessing the absolute and percentage numbers 
of T cell populations in peripheral blood, particularly of 
the naïve cells (CD45RA+CD62L+CD27+), and since 
these cells can have a long life (thousand to 10 thousand 
days), its amount in peripheral blood does not reflect only 
the recent thymic output; iii) Measurement of the TRECs 
(T-cell receptor excision circles) in the peripheral blood, 
a technique developed in the late 1990s and proposed as 
a measure of thymic T cells output, is still far from being 
widely introduced into clinical practice16,18,19. The TRECs 
represent a product of the rearrangement of genes encoding 
the TCR of T lymphocytes during their intrathymic 
maturation process18. The TRECs are episomal circles 
which do not replicate during mitosis, and thus are diluted 
with each cell division. In this way, clonal expansion after 
the encounter with the antigen should reduce the content 
of TRECs + cells [of that(those) clone(s)] within the total 
pool of T cells in the peripheral blood. As the production of 
TRECs+ naïve T cells is very low in other locations in the 
organism (intestines, for example), the number of TRECs+ 
naïve T cells has been considered as a reflex of the recent 
thymic production. However, in the interpretation of results, 
it is necessary to take into account, once more: i) the long 
lifespan of the naïve cells and ii) the speed of division of 
naïve cells in situations of infection, for example. The 
amount of TRECs+ cells is very high in early life, especially 
in the first three years, it remains high until adolescence, 
when it starts to lower, coinciding with the process of 
thymic involution16,20. Thus, there is a temporal relationship 
between the great volumes of the thymus in the first two 
decades of life and the increased production of naïve T cells 
reflected the higher concentration TRECs in the peripheral 
blood15. However, the doubt regarding the large thymuses 
seen in infants, whether they are functionally more active 
or not,  remains. In other words, it is not known if the large 
thymuses release a greater number of TRECs+ cells. They 
are always a reason to be concerned and require clinical 
and imaging monitoring. The parallel study of the TRECs 
could help in the clinical management of infants with “huge 
thymuses”. On the other hand, the blood concentrations 
of TRECs have been demonstrated to be very low in the 
DiGeorge syndrome (Figure 3) and in severe combined 
immunodeficiencies (SCID), and even in Down syndrome, 
situations in which it is known that the thymus does not 
fully develop19.
Some congenital diseases of the thymus
Although in the daily clinical practice the hypothesis 
that the thymus may be affected is exceptionally rare, there 
is an increasing number of descriptions of primary diseases 
of the thymus, with some examples in the following 
paragraphs, but there are also numerous situations in which 
the thymus may be secondarily affected, such as: the use of 
immunosuppressive drugs (probably also corticosteroids), 
including here situations of organ and tissue transplants, 
several autoimmune diseases, severe infections, nutritional 
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disorders, among other conditions which are common in 
clinical practice, especially among infants and children1,2,21. 
APECED (Autoimmune Polyendocrinopathy - 
Candidiasis - Ectodermal Dystrophy)
The identification of this rare disease, whose 
acronym became its name, and which is also called 
autoimmune polyendocrine syndrome type 1, stems from 
amorphic mutations in the AIRE gene, which encodes 
the autoimmune regulator transcription factor11.  It is an 
autosomal recessive defect that has a higher frequency in 
the inhabitants of the island of Sardinia, Finland, and among 
Iranian Jews. The patients suffer from multiple autoimmune 
endocrinopathies, from which hypoparathyroidism (present 
in 88% of the cases in literature) and Addison’s disease 
(84%) are the most common, followed by hypogonadism 
(69%), diabetes mellitus type I (33%) and hypothyroidism 
(31%)4. Chronic mucocutaneous candidiasis is present in all 
cases and is usually the first manifestation of the disease, 
which can already occur in the (very) first years of life. It is 
also currently considered as an autoimmune manifestation 
resulting from the action of anti-cytokine autoantibodies, 
in particular cytokine-neutralizing antibodies of the Th17 
pathway (IL-17, IL-17A and IL-22)22. So far, the therapeutic 
approach to patients with APECED has focused on the 
treatment of candidiasis and of the autoimmune diseases, 
with the necessary hormone replacement4.
The involution of the thymus during aging is also a process 
of great clinical interest1,3.
Figure 3. TRECs (T-cell receptor excision circles) blood levels from 27 patients with DiGeorge syndrome compared to age-matched 
healthy controls (data kindly provided by Dr. Leuridan Cavalcanti Torres)
Deficiency of the Foxn1
The four patients described in literature with 
a mutation on the FOXN1 gene showed absence of 
thymus, undetectable or a very low number of T cells in 
the peripheral blood (equivalent to those of SCID), the 
absence of hair and eyebrows, nail dysplasia, in addition 
to an increased susceptibility to infections23. One of the 
most recently reported cases is that of a Portuguese child 
who received thymic epithelium transplant with a quite 
satisfactory immunological reconstitution, however the 
description is that the child remains in complete alopecia. 
It is the human equivalent to the nude mouse, and this 
rare “experiment of nature” brings unique information on 
the key role of the Foxn1 transcription factor also for the 
development of the human thymus.
22q11.2 Deletion Syndrome (SD22q11.2)
SD22q11.2 [also called DiGeorge Syndrome (DGS) 
when associated to thymic alterations] is considered as the 
most common chromosomal microdeletion in humans. It is 
estimated that this syndrome happens at a frequency of 1: 
4,000 live births, which means that about 150 children with 
this condition are born each year in the State of São Paulo 
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(about 600,000 births/year )19,24. The most common clinical 
manifestations in SD22q11.2 are: congenital heart defects, 
particularly defects of the great vessels (75-80% of cases), 
hypocalcemia due to agenesia of the parathyroid glands 
(60%), facial dysmorphisms (Figure 4) and velopharyngeal 
insufficiency (46%) and immunological alterations, which 
vary greatly among those affected, resulting from thymus 
development disorders. It is estimated that in 1 to 2% 
of cases thymic agenesia occurs, and in the remaining 
cases there is the occurrence of hypoplasia of varying 
degrees12,19,24. Figure 4C shows a chest radiograph of an 
infant with DGS, where a thymic image cannot be observed, 
while Figure 3 presents the TRECs levels in some of the 
patients of the Children’s Institute, compared with controls 
of the same age, represented by patients who underwent 




Figura 4. Main phenotypic characteristics of patients with the DiGeorge syndrome: A) typical facies with narrow palpebral fissure, 
eyelid hooding, hypertelorism, square nose, elongated nose and face; B) infant with low implantation and dysplasic overfolded ears 
helix; C) the chest X-ray shows absence of thymic image (pictures kindly provided by Dr. Marcilia Sierro Grassi)
Despite the large number of cases already studied 
with DGS, it has not been possible to establish clear 
relationships between the clinical phenotype and the size 
of the chromosomal deletion24. Neither has it been possible 
to establish relationships between the size of the deletion 
and the degree of impairment of the thymic development 
and, therefore, with the severity of the immunodeficiency 
in the affected patients. Classic findings of the DGS have 
been described in patients with mutations in the TBX1 gene 
(encoded at the site of deletion), as well as malformations 
equivalent to that of this disease have been observed in 
knock-out mice for this gene. The immune deficiency 
observed in these patients is not only due to the quantitative 
deficiency of T cells as well as to abnormalities in the 
repertoire of T cells and reduction in their proliferation 
activity. Moreover, some patients present impairment of 
humoral immunity, with significant antibody disfunction. 
Autoimmune diseases, especially cytopenias, are not 
uncommon in DGS patients, and are more frequent than 
in the overall population11. The evaluation of humoral 
immunity in DGS has revealed that about 6% of those 
affected have significant hypogammaglobulinemia, 
requiring gamma-globulin replacement therapy25. 
Down Syndrome (DS)
The thymus of those affected by DS has been 
drawing attention since the 1970s, and has been described 
as having small dimensions, even in newborns and infants. 
The thymus presents an abnormal structure with some 
frequently observed histological changes, such as general 
hypocellularity, lack of clear demarcation between the 
cortical and medullary regions, narrowing of the cortex, 
huge Hassall corpuscles for one’s age), among other 
changes26,27,28,29. The TRECs concentrations have been 
presented as lower in peripheral blood when compared with 
age-matched controls and demonstrate the hypofunction 
of the thymus in patients with trisomy 21. Our research 
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group at Instituto da Criança (HC-FMUSP) observed a 
low expression of the AIRE protein and gene (encoded 
on 21q22.3) in thymuses of children with DS28. These 
patients have, in fact, some phenotypic characteristics in 
common with APECED: i) high frequency of organ-specific 
autoimmune diseases, especially endocrinopathies (in DS, 
especially hypothyroidism and diabetes mellitus type 1); 
ii) increased susceptibility to mucocutaneous candidiasis; 
and iii) the presence of autoantibodies which are unique 
to APECED. In this study, the reduced expression of Aire 
was observed both in infants and in older children, and the 
differences between patients and controls (patients with 
congenital heart disease (such) as an isolated malformation) 
were significantly higher (bigger) in patients (children) 
younger than one year of age. These results strongly 
suggest that the thymic alterations in DS are not caused by 
senescence of the immune system, but rather are present 
from the very beginning of development, and therefore 
must be caused by an intrinsic defect28. 
More recently, our group was able to characterize, 
in the human thymus, the transcriptional changes induced 
by trisomy 21 through the analysis of gene coexpression 
networks (GCNs) and microRNA-target interactions29. In 
this study we used cortical and medullary explants from 
thymic tissue - obtained in cardiac surgery in patients with 
DS and karyotipically normal controls (KNC) - and an 
approach to GCNs analysis that allows the identification of 
the repertoire of transcriptional modules (communities) and 
interactions between all the components of the system by 
detecting communities. Alterations in the degree observed 
connections for hubs/hierarchically important genes in 
KNC and DS networks corresponded to alterations in 
communities. The role of the miRNAS in modulationg 
the expression of highly connected genes in KNC and DS 
was revealed through the analysis of the miRNA-target 
interactions. The gene disruption caused by trisomy 21 
in the human thymus can be described as the disruption 
and altered reorganization of transcriptional modules. The 
leading GCNs acting in the normal state (KNC) and altered 
state (DS) of the thymus were identified. In summary, the 
KNC networks represent the thymus’ canonical way of 
functioning. On the other hand, the DS networks represent 
a non-canonical way, that is, adaptation of the thymic 
tissue under the gene disruption caused by trisomy 21. This 
adaptation is probably driven by epigenetic mechanisms 
occurring at the chromatin level and through miRNAs that 
control transcriptional programs involving high-hierarchy 
genes of the GCNs. 
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